Compare Stocks

Date Range: 

 Arcturus TherapeuticsAkero TherapeuticsEnanta PharmaceuticalsESSA PharmaPhibro Animal Health
SymbolNASDAQ:ARCTNASDAQ:AKRONASDAQ:ENTANASDAQ:EPIXNASDAQ:PAHC
Price Information
Current Price$31.80$27.33$48.50$29.73$27.45
52 Week RangeHoldBuyHoldBuyHold
MarketRank™
Overall Score1.61.71.41.41.7
Analysis Score3.14.53.11.50.8
Community Score2.62.42.33.12.2
Dividend Score0.00.00.00.02.5
Ownership Score1.71.71.72.51.7
Earnings & Valuation Score0.60.00.00.01.3
Analyst Ratings
Consensus RecommendationHoldBuyHoldBuyHold
Consensus Price Target$70.67$57.29$65.29$28.80$21.50
% Upside from Price Target122.22% upside109.61% upside34.61% upside-3.13% downside-21.68% downside
Trade Information
Market Cap$836.98 million$951.63 million$978.34 million$1.00 billion$1.11 billion
Beta3.010.580.541.960.46
Average Volume1,084,261282,931142,019328,505138,096
Sales & Book Value
Annual Revenue$20.79 millionN/A$122.47 millionN/A$800.40 million
Price / Sales40.26N/A7.99N/A1.39
CashflowN/AN/AN/AN/A$2.47 per share
Price / CashN/AN/AN/AN/A11.10
Book Value$1.70 per share$4.51 per share$22.70 per share$2.47 per share$4.65 per share
Price / Book18.71N/A2.14N/A5.90
Profitability
Net Income$-25,990,000.00$-43,760,000.00$-36,170,000.00$-23,440,000.00$33.55 million
EPS($2.15)($2.90)($0.89)($1.04)$1.08
Trailing P/E RatioN/AN/AN/AN/A25.90
Forward P/E RatioN/AN/AN/AN/A24.29
P/E GrowthN/AN/AN/AN/A2.00
Net Margins-506.70%N/A-29.53%N/A5.37%
Return on Equity (ROE)-52.32%-40.84%-3.75%-46.31%23.70%
Return on Assets (ROA)-33.21%-38.33%-3.53%-45.08%5.99%
Dividend
Annual PayoutN/AN/AN/AN/A$0.48
Dividend YieldN/AN/AN/AN/A1.75%
Three-Year Dividend GrowthN/AN/AN/AN/A20.00%
Payout RatioN/AN/AN/AN/A44.44%
Years of Consecutive Dividend GrowthN/AN/AN/AN/A1 Years
Debt
Debt-to-Equity Ratio0.06%N/AN/AN/A1.97%
Current Ratio11.21%24.81%18.08%66.75%2.88%
Quick Ratio11.21%24.81%18.08%66.75%1.61%
Ownership Information
Institutional Ownership Percentage74.33%83.49%90.78%63.37%50.32%
Insider Ownership Percentage12.60%7.09%10.93%N/A50.05%
Miscellaneous
Employees11821141251,700
Shares Outstanding26.32 million34.82 million20.17 million33.78 million40.45 million
Next Earnings Date5/10/2021 (Confirmed)5/12/2021 (Estimated)8/3/2021 (Estimated)8/5/2021 (Estimated)8/25/2021 (Estimated)
OptionableOptionableNot OptionableOptionableNot OptionableOptionable
SourceHeadline
Phibro Animal Health (NASDAQ:PAHC) Issues Q4 2021 Earnings GuidancePhibro Animal Health (NASDAQ:PAHC) Issues Q4 2021 Earnings Guidance
americanbankingnews.com - May 7 at 12:24 AM
Phibro Animal Health (NASDAQ:PAHC) Releases FY 2021 Earnings GuidancePhibro Animal Health (NASDAQ:PAHC) Releases FY 2021 Earnings Guidance
americanbankingnews.com - May 7 at 12:24 AM
Phibro Animal Health Corporation Reports Third Quarter and Year-to-Date ResultsPhibro Animal Health Corporation Reports Third Quarter and Year-to-Date Results
finance.yahoo.com - May 6 at 5:01 PM
Phibro Animal Health Co. Declares Quarterly Dividend of $0.12 (NASDAQ:PAHC)Phibro Animal Health Co. Declares Quarterly Dividend of $0.12 (NASDAQ:PAHC)
americanbankingnews.com - May 5 at 1:54 PM
Phibro Animal Health (NASDAQ:PAHC) Shares Gap Up to $24.52Phibro Animal Health (NASDAQ:PAHC) Shares Gap Up to $24.52
americanbankingnews.com - May 4 at 10:44 AM
Phibro Animal Health (NASDAQ:PAHC) Takes On Some Risk With Its Use Of DebtPhibro Animal Health (NASDAQ:PAHC) Takes On Some Risk With Its Use Of Debt
nasdaq.com - May 1 at 6:17 PM
 Analysts Expect Phibro Animal Health Co. (NASDAQ:PAHC) Will Post Earnings of $0.33 Per Share Analysts Expect Phibro Animal Health Co. (NASDAQ:PAHC) Will Post Earnings of $0.33 Per Share
americanbankingnews.com - May 1 at 4:12 PM
Phibro Animal Health (PAHC) Set to Announce Earnings on ThursdayPhibro Animal Health (PAHC) Set to Announce Earnings on Thursday
americanbankingnews.com - April 29 at 2:14 AM
Phibro Animal Health Corporation Announces $550 million Debt RefinancingPhibro Animal Health Corporation Announces $550 million Debt Refinancing
finance.yahoo.com - April 22 at 7:33 PM
 Brokerages Anticipate Phibro Animal Health Co. (NASDAQ:PAHC) Will Announce Earnings of $0.33 Per Share Brokerages Anticipate Phibro Animal Health Co. (NASDAQ:PAHC) Will Announce Earnings of $0.33 Per Share
americanbankingnews.com - April 14 at 4:44 PM
Heres Why You Should Add Phibro (PAHC) to Your PortfolioHere's Why You Should Add Phibro (PAHC) to Your Portfolio
finance.yahoo.com - April 12 at 12:57 PM
Phibro Animal Health Corporation to Host Webcast and Conference Call on March 2021 Quarterly Financial ResultsPhibro Animal Health Corporation to Host Webcast and Conference Call on March 2021 Quarterly Financial Results
finance.yahoo.com - April 8 at 6:32 PM
Phibro Animal Health Corporation to Participate in Bank of America Securities 2021 Virtual Healthcare ConferencePhibro Animal Health Corporation to Participate in Bank of America Securities 2021 Virtual Healthcare Conference
finance.yahoo.com - April 7 at 7:34 PM
PAHC or SRDX: Which Is the Better Value Stock Right Now?PAHC or SRDX: Which Is the Better Value Stock Right Now?
finance.yahoo.com - April 7 at 2:14 PM
Phibro Animal Health (PAHC)Phibro Animal Health (PAHC)
forbes.com - March 19 at 10:54 AM
Why Is Phibro (PAHC) Up 1.1% Since Last Earnings Report?Why Is Phibro (PAHC) Up 1.1% Since Last Earnings Report?
finance.yahoo.com - March 5 at 2:29 PM
Phibro Animal Health Corporation to Participate in the Barclays Virtual Global Healthcare ConferencePhibro Animal Health Corporation to Participate in the Barclays Virtual Global Healthcare Conference
finance.yahoo.com - February 8 at 5:48 PM
Phibro Animal Health Corporation to Participate in Bank of America Merrill Lynch 2021 Virtual Animal Health SummitPhibro Animal Health Corporation to Participate in Bank of America Merrill Lynch 2021 Virtual Animal Health Summit
finance.yahoo.com - February 8 at 12:47 PM
Phibro Animal Health Corporation Just Beat EPS By 28%: Heres What Analysts Think Will Happen NextPhibro Animal Health Corporation Just Beat EPS By 28%: Here's What Analysts Think Will Happen Next
nasdaq.com - February 5 at 9:43 AM
Phibro Animal Health Corp (PAHC) Q2 2021 Earnings Call TranscriptPhibro Animal Health Corp (PAHC) Q2 2021 Earnings Call Transcript
finance.yahoo.com - February 4 at 11:43 PM
Phibro Animal Health A is about to announce earnings — heres what Wall Street expectsPhibro Animal Health A is about to announce earnings — here's what Wall Street expects
markets.businessinsider.com - February 2 at 7:45 PM
PAHC vs. SRDX: Which Stock Should Value Investors Buy Now?PAHC vs. SRDX: Which Stock Should Value Investors Buy Now?
finance.yahoo.com - January 20 at 4:26 PM
Phirbo (PAHC) Nutritional Specialty Aids Growth, Low ASP AilsPhirbo (PAHC) Nutritional Specialty Aids Growth, Low ASP Ails
finance.yahoo.com - January 12 at 11:09 AM
Phibro Animal Health Corporation to Host Webcast and Conference Call on December 2020 Quarterly Financial ResultsPhibro Animal Health Corporation to Host Webcast and Conference Call on December 2020 Quarterly Financial Results
finance.yahoo.com - January 5 at 7:46 PM
Why Phibro Animal Health Corporation (NASDAQ:PAHC) Looks Like A Quality CompanyWhy Phibro Animal Health Corporation (NASDAQ:PAHC) Looks Like A Quality Company
finance.yahoo.com - December 25 at 3:00 PM
DateCompanyBrokerageAction
3/8/2021Arcturus TherapeuticsB. RileyLower Price Target
3/2/2021Arcturus TherapeuticsRoth CapitalLower Price Target
1/7/2021Arcturus TherapeuticsWells Fargo & CompanyInitiated Coverage
12/29/2020Arcturus TherapeuticsHC WainwrightDowngrade
12/29/2020Arcturus TherapeuticsRobert W. BairdDowngrade
12/29/2020Arcturus TherapeuticsBarclaysDowngrade
12/29/2020Arcturus TherapeuticsRaymond JamesDowngrade
12/14/2020Arcturus TherapeuticsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
12/14/2020Arcturus TherapeuticsSmith Barney CitigroupBoost Price Target
8/25/2020Arcturus TherapeuticsPiper SandlerInitiated Coverage
8/11/2020Arcturus TherapeuticsBrookline Capital ManagementReiterated Rating
3/29/2021Akero TherapeuticsMorgan StanleyLower Price Target
3/24/2021Akero TherapeuticsCanaccord GenuityLower Price Target
3/23/2021Akero TherapeuticsJefferies Financial GroupReiterated Rating
3/23/2021Akero TherapeuticsChardan CapitalBoost Price Target
3/4/2021Akero TherapeuticsGuggenheimInitiated Coverage
7/1/2020Akero TherapeuticsJPMorgan Chase & Co.Boost Price Target
2/9/2021Enanta PharmaceuticalsRoyal Bank of CanadaBoost Price Target
11/23/2020Enanta PharmaceuticalsEvercore ISIInitiated Coverage
9/23/2020Enanta PharmaceuticalsOppenheimerReiterated Rating
7/27/2020Enanta PharmaceuticalsJMP SecuritiesUpgrade
9/18/2019Enanta PharmaceuticalsBerenberg BankSet Price Target
5/24/2019Enanta PharmaceuticalsWolfe ResearchInitiated Coverage
8/8/2018Enanta PharmaceuticalsUBS GroupDowngrade
2/12/2021ESSA PharmaBloom BurtonReiterated Rating
5/8/2020Phibro Animal HealthCredit Suisse GroupLower Price Target
3/31/2020Phibro Animal HealthG.ResearchUpgrade
2/6/2020Phibro Animal HealthGabelliDowngrade
8/29/2019Phibro Animal HealthBank of AmericaLower Price Target
(Data available from 5/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.